Trial
NCT01687998
A Study of Evacetrapib in High-Risk Vascular Disease
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Eli Lilly and Company
Collaborators
The Cleveland Clinic
Condition
Cardiovascular Diseases
Intervention
Evacetrapib
Why stopped
Study termination due to insufficient efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-08